Avian reovirus vaccines
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorHolly S. Sellers
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses.
Claims23
An isolated avian reovirus, wherein the avian reovirus comprises:
- (a) a sigma C protein comprising an amino acid sequence with at least about 85% sequence identity to SEQ ID NO:2 and/or SEQ ID NO:4;
- (b) an S1 gene comprising a nucleotide sequence with at least about 85% sequence identity to SEQ ID NO:1 and/or SEQ ID NO:3;
- (c) a sigma C protein comprising an amino acid sequence with at least about 85% sequence identity to SEQ ID NO:6;
- or
- (d) an S1 gene comprising a nucleotide sequence with at least about 85% sequence identity to SEQ ID NO:5.
The avian reovirus strain 94594 of claim 6, wherein the avian reovirus strain 94594 is attenuated by at least 25 passages in an egg or a host cell line.
The avian reovirus strain 948264 of claim 8, wherein the avian reovirus strain 948264 is attenuated by at least 25 passages in an egg or a host cell line.
Dependencies are inferred from the claim text.